AKYA

Akoya Biosciences, Inc. (AKYA) | Rumor.io

Akoya Biosciences

AKYA

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about AKYA?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% new	0% 0	0% 0

May 21

Akoya Biosciences, Inc. (AKYA) received an unsolicited acquisition proposal from a third party to acquire the company in an all-cash tender offer transaction, with each share of AKYA common stock exchanged for $1.40 in cash.
The proposed offer price of $1.40 per share is lower than some analysts believe is necessary for a successful acquisition, and may not be sufficient to persuade AKYA to accept the offer.
For AKYA to be considered a buy, it needs to break through the $1.33 resistance level and close above it, which could lead to a squeeze in the stock price.

Generated by AI

Sentiment

Of the messages about AKYA that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	98.41% +15.08
Bearish	—	—	—	1.59% -15.08

Jan 10

The merger of Akoya Biosciences and Quanterix is expected to create a life sciences tools and emerging diagnostic company with a combined revenue of ~$220 million and a path to generating positive cash flow in 2026.
The combined balance sheet is expected to have approximately $175M in cash at the time of closing, likely in the second quarter of this year, with no expected debt.
The acquisition is expected to be accretive, with Akoya Biosciences shareholders receiving 0.318 shares of Quanterix common stock, and the combined entity trading at a premium to its current price.

Generated by AI

Topics

Of the messages about AKYA that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	0%	0%	0%
Announcements	—	100%	100%	94.29%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%
Technical Analysis	—	0%	0%	5.71%

Analysts· May 11

Analysts at Canaccord Genuity initiate coverage on Akoya Biosciences with a Buy rating and a $25 price target.
Piper Sandler analysts initiate coverage on Akoya Biosciences with an Overweight rating and a $28 price target.
JP Morgan analysts initiate coverage on Akoya Biosciences with an Overweight rating, with a $23 price target from Tycho Peterson and a $26 price target from another analyst.

Announcements· Jan 10

Quanterix Corporation has agreed to acquire Akoya Biosciences in an all-stock transaction, where Akoya will become a wholly owned subsidiary of Quanterix.
Akoya shareholders will receive 0.318 shares of Quanterix common stock for each share of Akoya common stock they own, valuing Akoya at approximately $3.73 per share.
The combined company will have a revenue of approximately $220 million, a path to generating positive cash flow in 2026, and an expected combined balance sheet of approximately $175M in cash at the time of closing.

Generated by AI

Community

Of the messages about AKYA, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	100%	100%	34.09%
Newcomers	—	0%	0%	65.91%

Jan 10

$AKYA is considered a potential buy with support at 2.50 and 3.80, with possible targets at 3.45, 4.30, and 4.50.
Quanterix is acquiring Akoya Biosciences in an all-stock transaction, with Akoya shareholders receiving 0.318 shares of Quanterix stock per share.
The technicals for $AKYA look weak, but the stock has momentum, with some users taking a chance on it despite the uncertain outlook.

Generated by AI

Also Discussed

Investors talking about AKYA also mention

#	Name	Attention
1	10x Genomics Inc. Class A Common StockTXG	0%-0.02
2	NaaS Technology Inc. ADRNAAS	0%0
3	Seer, Inc. Class A Common StockSEER	0%0
4	Bowhead Specialty Holdings Inc.BOW	0%-0.01
5	OLK - Olink Holding AB (publ)	——
6	IGMS - IGM Biosciences, Inc.	——
7	LCNB Corp.LCNB	0%0
8	Molecular Partners AG ADRMOLN	0%0
9	WAVS - Western Acquisition Ventures Corp.	——
10	OMIC - Singular Genomics Systems, Inc.	——